Abstract
Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
CNS & Neurological Disorders - Drug Targets
Title:Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders
Volume: 12 Issue: 5
Author(s): Shafiqur Rahman
Affiliation:
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
Abstract: Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Export Options
About this article
Cite this article as:
Rahman Shafiqur, Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050011
DOI https://dx.doi.org/10.2174/1871527311312050011 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Major Depressive Disorder and Magnetic Resonance Imaging: A Mini-Review of Recent Progress
Current Pharmaceutical Design Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis
Current Alzheimer Research P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Vitamin D-Binding Protein Acts in the Actin Scavenge System and Can Have Increased Expression During Aspirin Therapy
Current Neurovascular Research Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia
Current Alzheimer Research Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Which Treatment for Nonalcoholic Fatty Liver Disease?
Mini-Reviews in Medicinal Chemistry Epigenetic Studies in Psychotherapy: A Systematic Review
Current Psychiatry Research and Reviews Electro-Acupuncture Protects Diabetic Nephropathy-Induced Inflammation Through Suppression of NLRP3 Inflammasome in Renal Macrophage Isolation
Endocrine, Metabolic & Immune Disorders - Drug Targets